TY - JOUR
T1 - A Cross-Sectional Survey Study of Cannabis Use for Fibromyalgia Symptom Management
AU - Singla, Abhinav
AU - Anstine, Christopher V.
AU - Huang, Linda
AU - Rosedahl, Jordan K.
AU - Mohabbat, Arya B.
AU - Philpot, Lindsey M.
N1 - Publisher Copyright:
© 2024 Mayo Foundation for Medical Education and Research
PY - 2024/4
Y1 - 2024/4
N2 - Objective: To assess the use of cannabis as a symptom management strategy for patients with fibromyalgia. Patients and Methods: An electronic, cross-sectional survey was conducted among patients diagnosed with fibromyalgia and treated in Integrative Medicine & Health at Mayo Clinic, Rochester, Minnesota. The survey was constructed with the Symptom Management Theory tool and was sent anonymously via web-based software to patients with a diagnosis of fibromyalgia. Results: Of 5234 patients with fibromyalgia sent the online survey, 1336 (25.5%) responded and met the inclusion criteria. Survey respondents had a median age of 48 (Q1-Q3: 37.5-58.0) years, and most identified as female. Nearly half of respondents (49.5%, n=661) reported cannabis use since their fibromyalgia diagnosis. The most common symptoms for which respondents reported using cannabis were pain (98.9%, n=654); fatigue (96.2%; n=636); stress, anxiety, or depression (93.9%; n=621); and insomnia (93.6%; n=619). Improvement in pain symptoms with cannabis use was reported by 82.0% (n=536). Most cannabis-using respondents reported that cannabis also improved symptoms of stress, anxiety, and depression and of insomnia. Conclusion: Considering that cannabis is a popular choice among patients for managing fibromyalgia symptoms, clinicians should have adequate knowledge of cannabis when discussing therapeutic options for fibromyalgia with their patients.
AB - Objective: To assess the use of cannabis as a symptom management strategy for patients with fibromyalgia. Patients and Methods: An electronic, cross-sectional survey was conducted among patients diagnosed with fibromyalgia and treated in Integrative Medicine & Health at Mayo Clinic, Rochester, Minnesota. The survey was constructed with the Symptom Management Theory tool and was sent anonymously via web-based software to patients with a diagnosis of fibromyalgia. Results: Of 5234 patients with fibromyalgia sent the online survey, 1336 (25.5%) responded and met the inclusion criteria. Survey respondents had a median age of 48 (Q1-Q3: 37.5-58.0) years, and most identified as female. Nearly half of respondents (49.5%, n=661) reported cannabis use since their fibromyalgia diagnosis. The most common symptoms for which respondents reported using cannabis were pain (98.9%, n=654); fatigue (96.2%; n=636); stress, anxiety, or depression (93.9%; n=621); and insomnia (93.6%; n=619). Improvement in pain symptoms with cannabis use was reported by 82.0% (n=536). Most cannabis-using respondents reported that cannabis also improved symptoms of stress, anxiety, and depression and of insomnia. Conclusion: Considering that cannabis is a popular choice among patients for managing fibromyalgia symptoms, clinicians should have adequate knowledge of cannabis when discussing therapeutic options for fibromyalgia with their patients.
UR - http://www.scopus.com/inward/record.url?scp=85188709364&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85188709364&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2023.12.018
DO - 10.1016/j.mayocp.2023.12.018
M3 - Article
C2 - 38569809
AN - SCOPUS:85188709364
SN - 0025-6196
VL - 99
SP - 542
EP - 550
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 4
ER -